Literature DB >> 10471584

Mononuclear and polymorphonuclear leukocyte dispositions of clarithromycin and azithromycin in AIDS patients requiring Mycobacterium avium complex prophylaxis.

K Q Bui1, J McNabb, C Li, C H Nightingale, D P Nicolau.   

Abstract

The intracellular dispositions of clarithromycin and azithromycin in AIDS patients requiring Mycobacterium avium complex (MAC) prophylaxis were studied. The dispositions of both drugs in mononuclear and polymorphonuclear leukocytes were markedly different. Our data support the proven efficacy of these agents for MAC prophylaxis since clarithromycin and azithromycin displayed sustained intracellular concentrations which exceeded their MICs for MAC throughout the dosing periods.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10471584      PMCID： PMC89466     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Mean cell volume of human blood leucocytes and resident and activated murine macrophages.

Authors:  P H Nibbering; T P Zomerdijk; A J Corsèl-Van Tilburg; R Van Furth
Journal:  J Immunol Methods       Date:  1990-05-08       Impact factor: 2.303

Review 2.  The role of advanced generation macrolides in the prophylaxis and treatment of Mycobacterium avium complex (MAC) infections.

Authors:  G W Amsden; C A Peloquin; S E Berning
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

3.  Mycobacterium avium strains resistant to clarithromycin and azithromycin.

Authors:  L Heifets; N Mor; J Vanderkolk
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

4.  Uptake of azithromycin by various cells and its intracellular activity under in vivo conditions.

Authors:  A Wildfeuer; H Laufen; T Zimmermann
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

5.  Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group.

Authors:  D V Havlir; M P Dubé; F R Sattler; D N Forthal; C A Kemper; M W Dunne; D M Parenti; J P Lavelle; A C White; M D Witt; S A Bozzette; J A McCutchan
Journal:  N Engl J Med       Date:  1996-08-08       Impact factor: 91.245

6.  A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome.

Authors:  M Pierce; S Crampton; D Henry; L Heifets; A LaMarca; M Montecalvo; G P Wormser; H Jablonowski; J Jemsek; M Cynamon; B G Yangco; G Notario; J C Craft
Journal:  N Engl J Med       Date:  1996-08-08       Impact factor: 91.245

7.  Single- and multiple-dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial.

Authors:  S Chu; D S Wilson; R L Deaton; A V Mackenthun; C N Eason; J H Cavanaugh
Journal:  J Clin Pharmacol       Date:  1993-08       Impact factor: 3.126

Review 8.  Controversies in the management of Mycobacterium avium complex infection in AIDS patients.

Authors:  C A Peloquin
Journal:  Ann Pharmacother       Date:  1993 Jul-Aug       Impact factor: 3.154

Review 9.  The Mycobacterium avium complex.

Authors:  C B Inderlied; C A Kemper; L E Bermudez
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

10.  Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition.

Authors:  J P Chave; A Munafo; J Y Chatton; P Dayer; M P Glauser; J Biollaz
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.